DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) will deliver a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference in New York from September 9 to 11, 2024. The presentation will be accessible online starting at 7:00 A.M. (ET) on September 9 and remain available for 90 days.
Aprea, headquartered in Doylestown, Pennsylvania, focuses on precision oncology, employing synthetic lethality in its research. The company’s lead program, ATRN-119, is a small molecule ATR inhibitor targeting solid tumors. Additionally, APR-1051, a WEE1 inhibitor, has recently entered clinical trials. During the conference, management will engage in one-on-one meetings with institutional investors, enhancing opportunities for strategic partnerships and investment discussions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.